CONTROL OVER TOXICITY IN THE EVENT OF ANTI-TUMOR ACTIVITY OF CHEMICAL ANTIGEN RECEPTORS

摘要

The invention relates to compositions and methods for treating a malignant neoplasm in a patient. In one embodiment, the method includes first-line therapy, comprising administering genetically modified T cells expressing CAR to the patient, where CAR contains an antigen-binding domain, a transmembrane domain, a stimulatory signaling region, and a CD3 Zeta signaling domain, and monitoring cytokine levels in a patient after T infusion cells to determine the type of second-line therapy appropriate to the treatment of the patient due to the presence of CAR-T cells in the patient.